Drug intelligence / Profile preview

prulacel

Development stage: Preclinical
Lead developer: Adicet Bio
Modality: Cell Therapies
Administration: Intravenous

Overview

Prulacel is an "off-the-shelf" allogeneic gamma-delta T cell therapy under development by Adicet Bio. It is being investigated for its potential in treating cancer and autoimmune diseases. The drug's development and scalable manufacturing are supported through a collaboration with MaxCyte, which provides its non-viral, ex vivo cell engineering platform.

Other names: allogeneic CD19-directed GDT chimeric antigen receptor T-cell therapyallogeneic CD19-directed gamma delta CAR-T cell therapy

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on prulacel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on prulacel.

Explore the full profile